BeiGene
BGNE
$163.36
Share price
1.61%
Change (1 day)
-32.00%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Market capitalization of BeiGene (BGNE)
Market cap: $18.52 Billion
As of May 2024 BeiGene has a market cap of $18.52 Billion. This makes BeiGene the world's 1025th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of BeiGene from 2016 to 2024
End of year Market Cap
| Year | Market cap | Change |
|---|---|---|
| 2024 | $18.52 B | -6.5% |
| 2023 | $19.81 B | -15.53% |
| 2022 | $23.46 B | -14.65% |
| 2021 | $27.48 B | 14.39% |
| 2020 | $24.03 B | 133.57% |
| 2019 | $10.28 B | 23.44% |
| 2018 | $8.33 B | 87.28% |
| 2017 | $4.45 B | 269.44% |
| 2016 | $1.20 B |
End of Day market cap according to different sources
On May 14th, 2024 the market cap of BeiGene was reported to be:
$18.23 Billion
$18.23 Billion
$16.81 Billion
$15.38 Billion
Market capitalization for similar companies or competitors
| Name | Market cap | Market cap differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $0.92 B | -95.03% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $20.9 M | -99.89% | 🇺🇸 USA |